Remove 2023 Remove Court Decisions Remove Statute
article thumbnail

A Typical Eligibility Case in 2023

Patently O

As Congress continued to legislatively develop the statute, courts also added common law nuance, including the law of patent eligibility. Since 2012, almost 2,000 court decisions have referenced these cases along with 8,000+ PTAB decisions. The recent decision in Hawk Tech Sys. Prometheus , 566 U.S.

article thumbnail

SCOTUS Narrows Reach of Identity Fraud Statute

Constitutional Law Reporter

United States , 599 U.S. _ (2023), the U.S. Supreme Court narrowed the scope of a federal aggravated identity theft statute. Because everyday overbilling cases would account for the majority of vi- olations in practice, the Government’s reading places at the core of the statute its most improbable applications.

Statute 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

RabelsZ 87 (2023): Issue 4

Conflict of Laws

Symposium Introduction: Fundamental Rights and Private International Law after the Federal Constitutional Court Decision on the Act to Combat Child Marriages. Fundamental rights could – according to a first Constitutional Court decision – at most become relevant through the ordre public clause.

article thumbnail

The First Precedential Patent Decision of 2023: Dexcom v. Abbott Diabetes Care

Patently O

Court of Appeals for the Federal Circuit has begun 2023 with its first precedential patent decision in DexCom, Inc. 2023-1795 (Fed. In an opinion by Judge Stoll, the court affirmed a district court decision denying DexCom’s motion for a preliminary injunction. by Dennis Crouch The U.S.

article thumbnail

The Fourth Circuit Upholds CMS’ Definition of “Line-Extension Drug” and “New Formulation”

FDA Law Blog

Under the Medicaid Drug Rebate statute, a pharmaceutical manufacturer whose drug prices increase faster than the rate of inflation must pay additional per-unit rebates to the program. The statute defines a “line extension” as a “new formulation” of an existing drug, with certain exceptions. Vanda Pharmaceuticals, Inc. 23-1457 (4th Cir.

article thumbnail

D.C. Circuit Sides with Manufacturers in Latest 340B Contract Pharmacy Case

FDA Law Blog

Carole Johnson (consolidated cases), the Court found that the conditions set by Novartis and United Therapeutics on covered entities did not violate the 340B statute, although more restrictive conditions could violate the law. District Court and won, prompting a government appeal to the D.C.

article thumbnail

Federal ban on inducing unlawful immigration for financial gain may get another Supreme Court test

SCOTUSBlog

After a few slow weeks on the relist front, the Supreme Court came roaring back this week with four newly relisted petitions that, if granted, will likely be added to the March 2023 argument calendar. District courts have discretion to impose either consecutive or concurrent sentences unless a statute mandates otherwise.